Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. - Wikidata - wikimedia - TriplyDB

Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.

Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.

http://www.wikidata.org/entity/Q33373438

about

Treatment for small cell lung cancer, where are we now?-a review Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer Efficacy and safety of amrubicin hydrochloride for treatment of relapsed small cell lung cancer.Amrubicin for the treatment of neuroendocrine carcinoma of the gastrointestinal tract: a retrospective analysis of five cases.Retrospective analysis of Japanese patients with relapse or refractory small-cell lung cancer treated with amrubicin hydrochloride Phase II study of nedaplatin and irinotecan in patients with extensive small-cell lung cancer.A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer.Phase II study of amrubicin at a dose of 45 mg/m2 in patients with previously treated small-cell lung cancer.Correlation between the efficacy of amrubicin and the previous chemotherapy regimen for relapsed small cell lung cancer.Amrubicin monotherapy may be an effective second-line treatment for patients with large-cell neuroendocrine carcinoma or high-grade non-small-cell neuroendocrine carcinoma.Treatment options for small cell lung cancer - do we have more choice?Novel systemic therapies for small cell lung cancer Management of small-cell lung cancer: incremental changes but hope for the future The role of anthracyclines in small cell lung cancer.Review of the management of relapsed small-cell lung cancer with amrubicin hydrochloride.Current and emerging pharmacotherapies for the treatment of relapsed small cell lung cancer.Chemotherapy for small cell lung cancer: a comprehensive review Recurrent pulmonary synovial sarcoma effectively treated with amrubicin: A case report Efficacy of different monotherapies in second-line treatment for small cell lung cancer: a meta-analysis of randomized controlled trials.Second-line chemotherapy for refractory small cell neuroendocrine carcinoma of the esophagus that relapsed after complete remission with irinotecan plus cisplatin therapy: Case report and review of the literature.C609T Polymorphism of NADPH Quinone Oxidoreductase 1 Correlates Clinical Hematological Toxicities in Lung Cancer Patients Treated with Amrubicin.Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?Targeted therapies in small-cell lung cancer.Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial.Emerging drugs for small-cell lung cancer.Relapsed small cell lung cancer: treatment options and latest developments.Chemotherapy for lung cancer: the state of the art in 2009.Can anthracycline therapy for pediatric malignancies be less cardiotoxic?Update on new drugs in small cell lung cancer.Second-line therapy for small-cell lung cancer.Novel strategies for the treatment of small-cell lung carcinoma.Management of small cell lung cancer: recent developments for optimal care.Amrubicin: potential in combination with cisplatin or carboplatin to treat small-cell lung cancer.Chemotherapy advances in small-cell lung cancer Advances in pharmacotherapy of small cell lung cancer.Optimal drugs for second-line treatment of patients with small-cell lung cancer.The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer.Therapies in the pipeline for small-cell lung cancer.Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy.

P2860

Q26767023-D400201B-F0DD-4B61-B7AE-2F496B89F7F4 Q28072672-78987838-132B-4153-8BD7-A9AEB4A1E67D Q33383208-9DD92E7B-7DD3-4C30-8B68-BA64D2BC5B1C Q33393427-9F4F3553-0E0E-4016-B24D-A501D8EED0A5 Q33394763-D8B6A92D-0C48-46C7-8D3A-79D27FF85F24 Q33403230-B6A8D647-3D1F-49B6-A5FB-310B7F3324FA Q33404208-97E0A098-7ECC-40BF-9D83-C5478C01EEBA Q33416497-1223C438-EBA0-4CF4-8F9C-22FB9C98CBA6 Q33424869-FDA40996-E7C4-49EA-AE6C-2B6790525D91 Q33599044-F1649392-73D3-4487-A9F5-3DE8F3CEF67E Q33685826-97C6C9AB-4834-4793-80E7-0CE50ACABA14 Q33723735-096E6D63-3B73-403E-A92D-130AF79E0ED0 Q33862245-C94A89A4-CF00-4C83-BA61-2DECE7B9B34D Q34013813-471A5747-DEBD-4D09-A076-136D880C1091 Q34358063-3996D9EF-28F9-471D-93FA-3D1026508B5B Q34789076-BA603A3B-0BBA-4751-A1EA-D1CBEFFA32AE Q35155464-6C107161-0A97-4F84-A134-0600DFDF59BE Q35569379-68063EEB-E691-4424-8241-FFCAB32FF87C Q35754124-F949344B-98A4-4BBD-91D6-45137E2D7797 Q36412432-4D738BA2-519E-49AA-B5D5-4CFBF95B49A1 Q36475761-3DAE4A42-9AFA-465B-B85D-B856659730AD Q36622902-36A55A25-3E2A-4589-A70D-A07433F5FCDE Q36811784-5F9A677A-E48C-4345-94F3-9B1265F7F473 Q36897340-4350A9C6-E2BF-4BFC-848B-42ED27B04D83 Q36911934-27C4C498-60E3-4B50-A1BB-3B2F79BFB61A Q37582918-38E37EBC-D891-453E-A189-094C253E6AF1 Q37598178-C61E1E0D-0DA1-4727-8E30-ACD10C1EC1E8 Q37614566-B84BA040-9D30-406F-AAE5-8C0DCF263C7F Q37785821-83C60AB6-FE2D-4A11-95A0-3D7C3FCC6E7B Q37851992-30673663-4EF1-4657-B00E-CE1DEDAAA68C Q37866795-B0EA1802-A30A-44BE-A777-1418CE75F4F3 Q37892341-70509EBD-A57E-4DC8-88A6-418B06628646 Q37987205-BDAA8C41-03F9-4AE4-A7E3-9F146F7C4DAE Q38129050-262C87D4-BA5E-4528-AA95-0560A709B2A1 Q38155856-6BBC6448-13DA-4937-82CE-6F779CE4DE2C Q38254295-0260299B-450F-4EEF-8B7C-8FBD0D41E69A Q38734204-55580F5C-7C21-4E5C-8FD6-127B1C6C099A Q38847321-C54CB83D-C635-4789-8B7B-008ECDD94375 Q38871386-6CC97C1B-CECB-4995-9048-A5535F643BEF Q39259096-62B76BAC-3FA9-4F82-8EDE-FFA054410502

P2860

Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.

http://www.wikidata.org/entity/Q33373438

description

2006 nî lūn-bûn

@nan

2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Phase II trial of amrubicin fo ...... ogy Research Group Study 0301.

@ast

Phase II trial of amrubicin fo ...... ogy Research Group Study 0301.

@en

type

label

Phase II trial of amrubicin fo ...... ogy Research Group Study 0301.

@ast

Phase II trial of amrubicin fo ...... ogy Research Group Study 0301.

@en

prefLabel

Phase II trial of amrubicin fo ...... ogy Research Group Study 0301.

@ast

Phase II trial of amrubicin fo ...... ogy Research Group Study 0301.

@en

P1433

Q33373438-042F3606-C568-4367-8545-0466DB65525F

P1476

Q33373438-C9500D19-C8D3-4229-8C10-F04FE74ADA20

P2093

Q33373438-1078AC43-8F0A-49BB-BDEE-65C4793FE809

Q33373438-1A58533B-1B9D-4531-8632-96B1DB9E7E82

Q33373438-1CFC5AAB-C815-40D6-9720-546544090E3C

Q33373438-21723B38-F629-408F-A2B8-F14648638AE5

Q33373438-2EDD842B-E7FF-4A1E-A053-0336CD52EC2C

Q33373438-4773F511-4159-4E15-8247-AB82C8352841

Q33373438-618FDF05-3418-48BD-A571-9F9A7CA7B13E

Q33373438-677AFD59-F244-41FE-BC66-1EE947A3FD41

Q33373438-8374052C-4EB6-4B14-ABFD-FE57936B2E07

Q33373438-84F80104-0D59-4FE9-8D49-D40A8126174F

P304

Q33373438-94017867-FF34-45ED-89B6-BD5A2F3848ED

P31

Q33373438-653C47CB-D37B-40C5-A56E-07C2FFDB247A

P356

Q33373438-E1DF9208-7C21-4B01-B7B2-752DFA09F696

P407

Q33373438-4003CB75-88B0-40D1-9F56-02FB0B642839

P433

Q33373438-512FAFEB-20FB-424A-9E54-060B34F81356

P478

Q33373438-1DAC5E3C-0953-41C8-AF09-120A665D3E91

P577

Q33373438-E50894B2-F578-482B-8918-958B2B8AA39A

P698

Q33373438-91DBF095-D831-4C53-977B-66823A3F405D

P921

Q33373438-E1AAADC2-88F5-4026-92BE-1AED26DA85A7

P356

JCO.2006.08.4145

P1433

Journal of Clinical Oncology

P1476

Phase II trial of amrubicin fo ...... ogy Research Group Study 0301.

@en

P2093

Akihiro Tagawa

http://www.w3.org/2001/XMLSchema#string

Akira Yokoyama

http://www.w3.org/2001/XMLSchema#string

Hiroaki Okamoto

http://www.w3.org/2001/XMLSchema#string

Hiroshi Isobe

http://www.w3.org/2001/XMLSchema#string

Hiroshi Kunikane

http://www.w3.org/2001/XMLSchema#string

Kazutsugu Uematsu

http://www.w3.org/2001/XMLSchema#string

Kenji Eguchi

http://www.w3.org/2001/XMLSchema#string

Koshiro Watanabe

http://www.w3.org/2001/XMLSchema#string

Masanori Yokoba

http://www.w3.org/2001/XMLSchema#string

Masao Harada

http://www.w3.org/2001/XMLSchema#string

P304

5448-5453

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2006.08.4145

http://www.w3.org/2001/XMLSchema#string

P407

P433

34

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P577

2006-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17135647

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial